Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
January 2013, Vol 4, No 1
January 2013, Vol 4, No 1
Quality Oncology Practice Initiative Shows Strong Improvement in Some Care Measures
By
Caroline Helwick
ASCO’s 1st Quality Care Symposium
,
ASCO
January 2013, Vol 4, No 1
San Diego, CA—Adherence to several quality care standards markedly improved in practices participating in ASCO’s Quality Oncology Practice Initiative (QOPI) over a 4-year period, according to a study presented at ASCO’s inaugural 2012 Quality Care Symposium.
Read Article
“Dramatic” Responses with Targeted Agent for Patients with CLL
By
Charles Bankhead
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Atlanta, GA—Targeting Bruton’s tyrosine kinase (BTK) in patients with chronic lymphocytic leukemia (CLL) resulted in high response rates, without severe toxicity, according to the results of 2 studies that were presented at the 2012 American Society of Hematology meeting.
Read Article
Cost of Screening Mammography Varies by Strategy
By
Caroline Helwick
Health Economics
January 2013, Vol 4, No 1
San Antonio, TX—The national cost of screening mammography could vary by as much as $7 billion annually, depending on the screening strategy, according to a new study reported at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
Read Article
Ponatinib Produces High Response Rates in Hard-to-Treat Leukemia
By
Wayne Kuznar
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Atlanta, GA—The new oral tyrosine kinase inhibitor (TKI) ponatinib (Iclusig) has significant activity and is well tolerated in patients with highly pretreated chronic myeloid leukemia (CML) or with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) who otherwise lack therapeutic options.
Read Article
Page 4 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma